102 results about "Titer" patented technology

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

A system for measuring an antibody concentration in a sample includes a polarizer holder holding a first detection polarizer and a second detection polarizer, the first detection polarizer restricting fluorescence emitted from within a container to pass in a first direction. The second detection polarizer restricts fluorescence emitted from within the container to pass in a second direction. The second direction is perpendicular to the first direction. The system includes a detector for measuring fluorescence emitted in a first direction and fluorescence emitted in a second direction. The system rotates the polarizer holder in an alternating direction about an axis of rotation such that the first detection polarizer and the second detection polarizer are alternately placed in an optical path of fluorescence emitted from within the container.

This invention belongs to the fields of molecular biology and bioinformatics, specifically relating to a truncated bovine virus-encoded protein phage library, its construction method, and applications. This library covers all 162 known bovine viruses that host bovine subfamily viruses, containing 51,794 non-redundant peptide coding sequences of 56 amino acids each. These peptides are fused and displayed on the surface of the T7 phage capsid, with all coding sequences having a uniform total length of 200 bp. The library construction was achieved through sequence acquisition, truncation and redundancy removal, codon optimization and DNA synthesis, and in vitro ligation and packaging with T7 phage. The resulting library exhibits a positivity rate of 93% and a titer of 2.8 × 10⁻⁶. 10 PFU / mL. This invention features an optimized single-round high-throughput screening process adapted to clinical bovine serum samples, enabling efficient identification of bovine virus B-cell epitopes and providing tools and candidate targets for bovine virus vaccine development and diagnostic reagent development.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

The present application relates to the antibody of phorbolylated isocitrate dehydrogenase 1 and its preparation method and purpose, and specifically provides a polyclonal antibody, the polyclonal antibody is obtained by immunizing animals with the antigen epitope peptide of IDH1 phorbolylated, the specific site of the antigen epitope peptide is phorbolylated, and high-titer antibodies can be prepared, the phorbolylated modification of IDH1 in clinical specimens can be recognized with high specificity, and the polyclonal antibody can be used for the research of cell / tissue specimen immunoblotting and immunohistochemical method and the diagnosis of IDH1 related diseases.

The invention provides a method for predicting the ultraviolet inactivation effect of viruses in a liquid biological product. The method comprises the following steps: (1) detecting the absorbance value of a to-be-detected liquid biological product at a preset wavelength; (2) constructing a relation curve of the ultraviolet dose of the BSA / virus mixed solution and the decline degree of the virus titer; (3) constructing a relation curve of the ultraviolet dose of the SMZ working solution and the SMZ degradation degree; (4) constructing a relation curve of the operation parameters and the SMZ degradability; and (5) substituting preset operation parameters into the relation curve of the operation parameters and the SMZ degradability, substituting the obtained result into the relation curve of the ultraviolet dose and the SMZ degradability, substituting the obtained result into the relation curve of the ultraviolet dose and the decline of the indication virus titer, and judging the ultraviolet inactivation effect of the virus according to a predicted value of the decline of the indication virus titer. The method is accurate in prediction result, does not need to consume liquid biological products, and can be used for various virus inactivation effects under the condition that the ultraviolet dose cannot be accurately calculated.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

This invention relates to a high-titer prealbumin antibody purification method and its application, belonging to the field of biotechnology. The method utilizes Protein A affinity chromatography to capture total IgG from antiserum, followed by purification using an affinity chromatography column prepared by targeted conjugation of a specific sequence peptide. The antibody purified by this method achieves a titer of 1:256,000 in ELISA detection, with a half-maximal effective concentration (EC50). 50 The antibody concentration was 3.2 ng / mL, exhibiting extremely high affinity and reactivity. When used in a double-antibody sandwich chemiluminescent immunoassay, it achieved a detection limit of 0.08 µg / mL, a wide dynamic range (0.08–400 µg / mL), and a titer retention rate as high as 88% after accelerated storage at 37°C for 14 days, demonstrating significantly better stability than antibodies prepared by traditional methods. This invention provides a highly active and stable core antibody raw material for the preparation of high-performance immunodiagnostic reagents.

The invention discloses a neutralizing antibody with an AQP3 channel blocking function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neutralizing antibody can be specifically combined with an extracellular domain of AQP3, after combination, a water channel and a small molecule transport function of the AQP3 are blocked through steric hindrance and conformation change, and meanwhile, antigen combination specificity is reserved. The preparation method is realized through'recombinant antigen-immunization-B cell screening culture-recombinant antibody expression and affinity purification-ELISA detection ', and the functions of the antibody are ensured. The antibody can be efficiently combined with AQP3 positive cells, is strong in targeting property and high in specificity (the serum titer reaches 1: 1024 * 10, and the purified antibody titer is greater than or equal to 1: 128 * 10), and can be independently used or combined with a nano-carrier for treating related diseases, so that the technical bottleneck that a common AQP3 antibody can only be combined and cannot efficiently play a blocking role is solved.

The invention provides a high-yield rabies virus cell line as well as a preparation method and application thereof. Specifically, the invention provides an engineered cell for producing the recombinant rabies virus, the recombinant rabies virus with effective titer can be produced by using the cell virus through one-time passage, and a neural circuit tracing tool with excellent performance is provided for the application of the defective rabies virus in neural network reverse labeling. The research in the brain science field is promoted.

The invention belongs to the technical field of biological medicine, and discloses an antibody for treating advanced rectal cancer and application thereof.The antibody is a monoclonal antibody 3C1 of targeted carcino-embryonic antigen (CEA), the sequence of a heavy chain variable region (VH) of the antibody is as shown in SEQ ID NO: 1, the sequence of a light chain variable region (VL) of the antibody is as shown in SEQ ID NO: 5, and the indirect ELISA detection titer reaches 1: 512000; also provided is an antibody conjugate (ADC) in which the antibody and raltitrexed are coupled by a linker, the drug-antibody ratio (DAR) being 3.0-4.0, the monomer purity being greater than or equal to 95%; the antibody conjugate (ADC) can be used for treating CEA positive advanced rectal cancer, animal experiments show that the tumor inhibition rate of ADC is 86% (significantly higher than 35% of free raltitrexed), the weight loss rate of mice is low, the toxicity of small intestines is light, the problems that existing drugs are poor in targeting and high in toxicity are solved, and the antibody conjugate has the advantages of high efficiency and safety.

The present application relates to a kind of mycophenolic acid detection reagent and its preparation and detection method, specifically a kind of mycophenolic acid chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti mycophenolic acid specific antibody, for detecting the indicating reagent of anti mycophenolic acid specific antibody-mycophenolic acid combination;The above anti mycophenolic acid specific antibody is obtained by mycophenolic acid immunogen immunization animal.The present application has the advantages that: the mycophenolic acid immunogen of the present application is specific, and immunogenicity is high, and the prepared anti mycophenolic acid specific antibody is specific, and titer is high;Chemiluminescence immunoassay reagent containing the above anti mycophenolic acid specific antibody can determine the mycophenolic acid content in sample conveniently, quickly and accurately, and multiple samples can be simultaneously determined on full-automatic chemiluminescence immunoassay analyzer, realize the high-throughput rapid determination of mycophenolic acid, and the accuracy is high, and the specificity is strong, and accuracy and detection efficiency have been greatly improved.

The invention relates to the technical field of syphilis detection, in particular to a method and a system for rapidly detecting negative endpoint titer. The method comprises the following steps: (1) obtaining a reaction result image of a non-treponema pallidum antigen serum test result; (2) inputting the reaction result image into a reaction intensity classification model, and outputting reaction intensity classification; determining dilution multiples for next detection according to the reaction intensity classification, and skipping unnecessary dilution multiples; and (3) preparing a new to-be-detected sample according to the dilution ratio determined in the step (2), and repeating the steps (1) and (2) until the output result of the reaction intensity classification model is negative, so as to obtain a negative endpoint titer. The novel method for detecting the negative endpoint titer and the corresponding system are obtained by combining deep learning technology research, the syphilis negative endpoint titer detection efficiency and accuracy are remarkably improved, test reagents are saved, and the method and the system have important application value.

The present application provides a method for detecting a virus solid rate. The virus has a capsid and a nucleic acid molecule contained in the capsid, and the method comprises: using a first dye to label the capsid of the virus in a sample containing the virus, and detecting the number of events showing fluorescence positivity after being labeled by the first dye; destroying the capsid of the virus, and then using a second dye to label the nucleic acid molecule, and detecting the number of events showing fluorescence positivity after being labeled by the second dye; and calculating the solid rate of the virus according to the number of events showing fluorescence positivity after being labeled by the first dye and the number of events showing fluorescence positivity after being labeled by the second dye.

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The application provides a composition, a method and an application for improving the titer of mouse leukemia virus, and belongs to the technical field of biotechnology.The method comprises the following steps: before a host cell is infected with xenotropic mouse leukemia virus, the host cell is pretreated by using SC79; during virus infection of the pretreated host cell and during cell passage, mifepristone is added to a culture medium; and during continuous virus harvesting, LR3 IGF-1 is added to the culture medium.Through adding additives with different functional mechanisms at different stages of virus production, the application realizes dynamic optimization of the whole process of virus production.The experimental results show that the combination of SC79, mifepristone and LR3 IGF-1 can increase the titer of xenotropic mouse leukemia virus by 14.32 times, which is significantly better than the effect of single additive or two additives in combination.The application solves the problems of low titer of virus stock solution and low production efficiency in the prior art.

The invention provides a method for detecting the protein state of gene-edited cynoglossus semilaevis Dmrt1, namely a protein immunodetection method based on an antigen and an antibody thereof is established on the basis of designing and obtaining optimized antigen polypeptide capable of specifically recognizing gene-edited derived protein, so that accurate identification and product monitoring of the gene-edited cynoglossus semilaevis are realized. The amino acid sequence of the antigen polypeptide is SEQ ID NO: 2. The optimized antigen capable of specifically recognizing a gene editing product is obtained through design and is used for preparing a high-titer antibody and developing a detection product, so that a method for directly and accurately identifying the gene editing cynoglossus semilaevis at the protein level is established, the defect that the edited protein product cannot be detected in the prior art is overcome, and the detection efficiency is improved. And a key tool is provided for functional verification and biological safety evaluation of the gene editing fish.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The invention relates to the field of biotechnology and molecular detection, and particularly provides a conjugate and application thereof, the conjugate comprises a solid phase carrier; the substance is coupled with the solid phase carrier and specifically binds to the p24 protein. The conjugate provided by the invention can accurately evaluate the p24 protein content of lentivirus particles without being influenced by the content of free p24 protein in a solution, so that an accurate lentivirus titer result is obtained, and the process stability and accuracy in the lentivirus production process are improved.

The application provides an avian PCV3 gene and application thereof, and belongs to the technical field of animal virology and immunology. The application provides an avian PCV3 gene for the first time, which is named aPCV3, and the nucleotide sequence of the aPCV3 gene comprises any one of SEQ ID NO. 1-2 or a sequence with a homology of more than 90% with SEQ ID NO. 1 and 2. The virus strain containing the aPCV3 gene has a high virus titer and can be stably passaged for multiple times. The inactivated vaccine prepared from the virus strain containing the aPCV3 gene and the subunit vaccine prepared from the Cap gene or the Rep gene in the aPCV3 gene have a significant protective effect on poultry such as chickens, ducks and geese. The ELISA detection plate prepared from the Cap gene or the Rep gene in the aPCV3 gene can accurately detect PCV3 and has high specificity and repeatability.

The present application relates to the field of immunoassay technology, and provides a myclobutanil hapten, antigen, antibody and preparation method and application. The present application introduces an active group at the meta position of the chlorine atom on the benzene ring of myclobutanil. Compared with the existing hapten, the hapten provided by the present application completely simulates the structure of myclobutanil, and enhances the immunogenicity of the antigen. The antigen provided by the present application has strong immunogenicity after being coupled with a carrier protein. After injection immunization of mice, the titer of the produced antibody is 5.0x10 4 , the half-inhibitory concentration (IC 50 ) is about 50 ppb, and the minimum detection limit of colloidal gold for myclobutanil in dry tobacco leaf samples is about 2.5 μg / g.

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

The invention discloses an antibody aiming at 2-87 site amino acid fragments of PRRSV (porcine reproductive and respiratory syndrome virus) N protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof has broad-spectrum recognition capability on different genotypes of PRRSV, is high in specificity and titer, can be used for preparing a PRRSV detection reagent or kit, realizes rapid and accurate preliminary screening of PRRSV infection, and can be used for detecting PRRSV infection. The problems of single target spot, insufficient specificity, dependence on import of core reagents and the like in the existing detection technology are solved, a key biological reagent is provided for prevention and control of PRRS, and the kit has important practical application value.

The invention relates to the technical field of biology, in particular to a chicken-derived riemerella anatipestifer disease trivalent inactivated vaccine. The inactivated vaccine contains a chicken source riemerella anatipestifer inactivated antigen and an SEPPIC water adjuvant MONTANIDE GEL 02 PR, wherein the chicken source riemerella anatipestifer inactivated antigen is prepared from the chicken source riemerella anatipestifer; the inactivated antigen is a serum type 1 chicken source riemerella anatipestifer DHN-2025-RA-CK018 strain, a serum type 5 chicken source riemerella anatipestifer DHN-2025-RA-CK006 strain and a serum type 10 chicken source riemerella anatipestifer DHN-2025-RA-CK033 strain, the inactivated antigen is preserved in Guangdong Province Microbial Culture Collection Center in August 28, 2025, and the preservation numbers of the inactivated antigen are GDMCC NO: 66885, GDMCC NO: 66884 and GDMCC NO: 66886 respectively. The vaccine can effectively induce a high-titer protective antibody and resist corresponding serotype infection. In addition, the safety of the vaccine is effectively improved by adopting a novel polymer water adjuvant of French Saccharomyces cerevisiae MONTANIDE GEL 02 PR. Meanwhile, the invention also discloses a preparation method of the vaccine.

The application discloses an anti-MAK16-IgG1 monoclonal subtype antibody and a preparation method and application thereof, and belongs to the technical field of immunological disease drugs. The application successfully prepares a high-concentration high-purity monoclonal antibody against MAK16 protein, which is a monoclonal IgG1 subtype antibody, namely anti-MAK16-IgG1 monoclonal subtype antibody; the titer is 160000; compared with RAW264.7 cells in a group stimulated and induced by IgG1+LPS, the expression amounts of IL-6 and IL-10 in RAW264.7 cells after 24h and 48h of stimulation and induction by the anti-MAK16-IgG1 monoclonal subtype antibody prepared by the application and LPS are significantly reduced, and the difference is more obvious with the prolongation of time; the effective dose of the anti-MAK16-IgG1 monoclonal subtype antibody is not less than 50 mu g / mL.

A system for measuring the concentration of antibodies in a sample includes a polarizer holder that holds a first detection polarizer and a second detection polarizer. The first detection polarizer restricts the passage of light fluorescing from within the container in a first direction. The second detection polarizer restricts the passage of light fluorescing from within the container in a second direction, which is perpendicular to the first direction. The system includes a detector for measuring light fluorescing in the first direction and light fluorescing in the second direction. The system rotates the polarizer holder around a rotation axis in alternating directions, causing the first and second detection polarizers to alternately position within the optical path of light fluorescing from within the container.

This invention discloses self-assembled ferritin nanoparticles and their application in the preparation of duck hepatitis A vaccine. The invention connects the VP1 portion of the duck hepatitis A virus P1 protein to the N-terminus of a self-assembled ferritin nanoparticle subunit via a linker sequence to obtain a fusion protein, the amino acid sequence of which is shown in SEQ ID NO.1. To improve the expression level or efficiency of the fusion protein in silkworms, the nucleotide sequence of the encoding gene of the fusion protein is optimized and modified according to the codon preference of silkworms, resulting in the optimized gene sequence shown in SEQ ID NO.2. The invention also involves single-site or multi-site mutations of the fusion protein, screening for mutants with significantly improved titers and significantly increased soluble expression levels. This invention utilizes a silkworm or insect cell eukaryotic expression system to express the recombinant protein, and the expression product induces neutralizing anti-duck hepatitis A virus antibodies.

The invention provides a detection method of replicating adeno-associated viruses and a kit thereof. The detection method comprises three rounds of amplification and detection processes, wherein the detection process comprises the following steps: extracting virus DNA of a supernatant of the first round of amplification, a supernatant of the second round of amplification and / or a supernatant of the third round of amplification, and carrying out quantitative PCR genome titer detection on the virus DNA and a replicated adeno-associated virus standard substance through a specific primer and a Taqman probe; the sequence of the specific primer is as shown in SEQ ID No. 3-4, and the sequence of the Taqman probe is as shown in SEQ ID No. 5. The invention provides a detection method for rapidly detecting the content of the replicating adeno-associated virus in a recombinant adeno-associated virus product in a short time, the amplification of the replicating adeno-associated virus can be successfully realized by culturing the detection system for 24 hours, the sample detection period is greatly shortened, and the quality control pressure is relieved.

The invention discloses an automatic liquid mixing method for virus titer detection based on a plaque method, which utilizes an execution module to automatically transfer liquid, separate the liquid and mix the liquid, greatly improves the liquid mixing efficiency, and can greatly reduce the manual workload and save time and cost especially for the detection task of batch liquid preparation and liquid mixing. Liquid is obtained strictly according to a preset sequence by means of the execution module and injected into the mixing tube, so that the host cell liquid, the virus test sample and the liquid agar are injected into the same mixing tube firstly, the steps in the whole liquid mixing process are smoothly linked and are high in efficiency, and it is guaranteed as much as possible that only one virus invades one host cell; and the accuracy of the virus titer detection result based on the plaque method is improved.